Molecule
Triamcinolone acetonide extended-release injectable suspension is a prescription medicine indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. It is available as kits for intra-articular use. MedsAcross supplies Triamcinolone acetonide extended-release injectable suspension for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. ZILRETTA is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management of osteoarthritis pain of the knee. Limitation of Use The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Source: US FDA prescribing information
Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.
Source: US FDA prescribing information
32 mg (5 mL) administered as a single intra-articular injection in the knee. See Instructions for Use (IFU) for instructions on reconstitution of ZILRETTA with the supplied diluent. It is normal for some residue to be left behind on the vial walls after withdrawing the suspension. ZILRETTA is NOT substitutable with other formulations of injectable triamcinolone acetonide.
Source: US FDA prescribing information
ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product. Patients with hypersensitivity to triamcinolone acetonide or any component of the product.
Source: US FDA prescribing information
Intra-articular Use Only: Do not administer ZILRETTA by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use. Hypersensitivity Reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care upon occurrence of an anaphylactic reaction. Joint Infection and Damage: May cause joint pain accompanied by joint swelling. If this occurs, conduct appropriate evaluation to exclude septic arthritis and institute appropriate antimicrobial therapy if septic arthritis is confirmed.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling. Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration Hypersensitivity Reactions Joint Infection and Damage Increased Risk of Infections Alterations in Endocrine Function Cardiovascular Effects Renal Effects Increased Intraocular Pressure Gastrointestinal Perforation Alternations in Bone Density Behavioral and Mood Disturbances Most commonly reported adverse reactions (incidence ≥1%) in clinical studies include sinusitis, cough, and contusions.
Source: US FDA prescribing information
No drug-drug interaction studies have been conducted with ZILRETTA. Table 3 contains drug interactions associated with systemic corticosteroids. Table 3: Drug Interactions Associated with Systemic Corticosteroids Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), observe patients closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
Source: US FDA prescribing information
Store vials in carton.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Triamcinolone acetonide extended-release injectable suspension, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zilretta kitIntra-articular | Pacira Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Triamcinolone acetonide extended-release injectable suspension and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Triamcinolone acetonide extended-release injectable suspension, including Zilretta.
No listed presentation of Triamcinolone acetonide extended-release injectable suspension is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.